Elanco Animal Health Incorporated Goodwill, Foreign Currency Translation Gain (Loss)
Elanco Animal Health Incorporated (ELAN) reported Goodwill, Foreign Currency Translation Gain (Loss) of $365.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-02-24
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for the quarter ending 2024-12-31 was -$211.00M, a 211.05% decline year-over-year.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for the quarter ending 2024-09-30 was $145.00M.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for the quarter ending 2024-06-30 was -$22.00M.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for the quarter ending 2024-03-31 was -$134.00M.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for fiscal 2025 was $365.00M.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for fiscal 2024 was -$222.00M, a 259.71% decline from fiscal 2023.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for fiscal 2023 was $139.00M.
- Elanco Animal Health Incorporated goodwill, foreign currency translation gain (loss) for fiscal 2022 was -$179.00M.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $365.00M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | -$211.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$66.00M derived: sum of 2 quarters · filed 2026-02-24 | -$88.00M derived: sum of 3 quarters · filed 2026-02-24 | -$222.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $145.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $123.00M derived: sum of 2 quarters · filed 2024-11-07 | -$11.00M 10-Q · filed 2024-11-07 | $179.00M derived: sum of 4 quarters · filed 2025-02-25 |
| 2024-06-30 | -$22.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$156.00M 10-Q · filed 2024-08-08 | $34.00M derived: sum of 3 quarters · filed 2025-02-25 | |
| 2024-03-31 | -$134.00M 10-Q · filed 2024-05-08 | $56.00M derived: sum of 2 quarters · filed 2025-02-25 | ||
| 2023-12-31 | $190.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $139.00M 10-K · filed 2025-02-25 | ||
| 2023-09-30 | -$51.00M 10-Q · filed 2023-11-07 | |||
| 2022-12-31 | -$179.00M 10-K · filed 2024-02-26 | |||
| 2021-12-31 | -$229.00M 10-K · filed 2023-03-01 | |||
| 2020-12-31 | $195.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $293.70M 10-K · filed 2021-03-01 | ||
| 2020-09-30 | $97.90M 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |